Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp., trading under the ticker DMAAR, is a blank-check company focused on the domestic pharmaceutical manufacturing sector. The SPAC filed a Form 10-Q with the SEC on May 20, 2025, reflecting its continued search for a business combination target within the healthcare and drug-production industry. The vehicle targets companies aligned with domestic pharmaceutical supply chain and manufacturing operations, a sector that has drawn heightened regulatory and investor attention in recent years. DMAAR remains in its search phase as of its most recent quarterly filing. Visit SpacDesk and sign up for full data, filings, and deal-tracking on DMAAR and hundreds of other active SPACs.